In partnership with:
Date:
18 September 2025, 11:00 AM –12:00 PM CEST
Overview:
This session highlights recent innovations and practical strategies in antimalarial drug discovery, including advanced screening techniques, novel compound development, and data-driven decision-making across the R&D pipeline. Gain insights into how mechanistic understanding of parasite resistance and optimization of pharmacokinetic parameters are accelerating candidate selection and enhancing therapeutic efficacy.
What you will learn:
- Explore the strengths and applications of phenotypic vs. target-based screening in antimalarial drug discovery.
- Learn how structure-activity relationship (SAR) optimization drives the development of more effective compounds.
- Understand the molecular mechanisms behind next-generation antimalarial agents.
- Discover strategic approaches to overcoming and mitigating parasite drug resistance.
Speakers:
Gang Liu, Ph.D.
Senior Program Officer
Gates Foundation
Brice Campo, Ph.D.
Head of Biology and Innovative Technologies
Medicines for Malaria Venture
James Duffy, Ph.D.
Senior Director of Drug Discovery
Medicines for Malaria Venture
Jeremy Burrows, Ph.D.
VP, Head of Discovery
Medicines for Malaria Venture
Dominique Besson, MBA
Associate Director of Discovery Data & Alliance Management
Medicines for Malaria Venture
Kelly Chibale, Ph.D.
Professor of Organic Chemistry
University of Cape Town
Elizabeth Winzeler, Ph.D.
Associate Dean and Professor
University of California, San Diego
Mariana Vaschetto, Ph.D.
Director Of Operations EMEA-AP-LATAM
Collaborative Drug Discovery
Dylan Kissane
Host and Director of Editorial
Labiotech